01/02/2026
As we close out 2025, we’re humbled and grateful for what this year has brought and what lies ahead. At Vast Therapeutics, our mission has always been clear: to develop breakthrough therapies that help people with chronic lung disease breathe better and live more fully.
This year brought meaningful milestones toward that mission:
-We completed a key milestone in our Phase 1 clinical program for our lead candidate ALX1, advancing it safely and thoughtfully through important early testing.
-We were awarded significant NIH funding to support our work against rare and challenging lung infections, a vital step forward in our science and hope for patients.
-Our team secured orphan and qualified infectious disease designations, reflecting the potential impact our therapies could have for people with rare respiratory diseases.
None of this would be possible without the support of our community: patients, partners, researchers, and believers in better respiratory health.
Thank you for your trust, encouragement, and shared commitment to innovation that matters.
Here’s to moving closer to transformative medicines in 2026 and beyond together.
💙 With gratitude,
Team Vast Therapeutics
